Clinical trial · Interventional
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma
NCT01203618CI-TRIAL-00012518withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Trial terminated due to focus of primary therapeutic areas.
Summary
Brief summary (as posted)
The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Resectable, Non-functioning Pituitary Adenoma | Pituitary Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Farletuzumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Efficacy of farletuzumab in subjects with resectable, non-functioning pituitary macroadenomas as measured by objective response in the tumor size.
- timeFrame
- Every 3 months
Secondary outcomes (1)
- measure
- Safety and tolerability of farletuzumab in this patient population.
- timeFrame
- Weekly for the first 3 months followed by every 2 weeks for 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Males and females \>18 years old * Diagnosis of non-functional pituitary adenoma * Able and willing to undergo surgical resection of the pituitary tumor * Significant medical conditions must be well-controlled and stable for at least 30 days prior to signing the informed consent form Exclusion Criteria: * Presence of clinically significant pituitary apoplexy * Presence of hormone-secreting adenomas * Presence of compressive optic neuropathy due to pituitary tumor * No prior surgical, medical, or radiation therapy in the last 6 months
References
Publications (0)
Data not yet available
No reference posted for this study.